ARTICLE | Finance
Asset-centric milestone
Lilly-Arteaus deal provides Atlas Venture with first asset-centric graduation
January 20, 2014 8:00 AM UTC
Atlas Venture and Eli Lilly and Co. both checked first-time milestones when the pharma decided to reacquire its anti-CGRP antibody for migraine prevention from Arteaus Therapeutics LLC.
Last week, Lilly exercised its option to reacquire LY2951742 from Arteaus after the compound met the primary and secondary endpoints in a Phase II trial to prevent frequent recurrent migraines. The pharma said it plans to start a Phase IIb trial this year...